Maiden’s managing director, Naresh Kumar Goyal, did not immediately respond to calls and messages.
The World Health Organization (WHO) in October said four medicinal syrups made by Maiden and imported by a local wholesaler were likely linked to the deaths, which have shocked the West African country since July. The drugs were pulled from the shelves and Maiden's production licence in India was suspended.
After its investigation, Gambia's select committee on health reached a similar conclusion.
"All the cases of AKI are linked to the consumption of contaminated medical products...manufactured by Maiden Pharmaceuticals," the committee's chairperson Amadou Camara said in a statement to parliament.
Goyal said that his company had done no wrong.
The WHO in October said that lab analysis confirmed "unacceptable" amounts of diethylene glycol and ethylene glycol in the medicines made by Maiden, which can be toxic and lead to acute kidney injury.
Earlier this month India told the WHO that tests of samples from the same batches of syrups that were sent to Gambia were compliant with government specifications.
Reuters, the news and media division of Thomson Reuters, is the world's largest multimedia news provider, reaching billions of people worldwide every day.Go to: https://www.reuters.com/